Our Company

Dialyfix® develops innovative implantable medical devices for fistula-free hemodialysis™ treatment for an estimated 5+ million end-stage kidney disease patients. Currently, the company is working towards its First-in-Human clinical study.

Located in France, Dialyfix® is using just-in-time ISO 13485-certified external resources with cutting edge expertise in R&D, manufacturing, clinical applications, and regulatory and legal affairs.

The Company will be relying on a world-wide network of partners and distributors for marketing and sales.

Leadership

Sorin Grunwald, Phd MBA, is a medical industry enthusiast with relevant experience and expertise, who started several medical device companies and contributed to the development of several new medical device products in Europe and in the USA.

Sorin Grunwald PhD MBA

President and Founder

Achievements: Entrepreneurship and Leadership

• President and founder, Dialyfix® SAS (France).

• President and CEO, co-founder, Romedex sarl (Romania), technology acquired by BD / Bard.

• CEO and VP R&D, co-founder, Vasonova Inc. (USA), acquired by Teleflex Medical.

• Sr. Manager, Boston Scientific Corporation (USA).

• VP R&D, co-founder, WMT GmbH (Germany), acquired by Dornier MedTech.

Achievements: Product Development

• 35 issued patents.

• Development of US FDA-approved and CE-marked products.

Achievements: Research

• Artificial Intelligence applied to medical image and signal processing and interpretation.

• One book and 20+ published papers.

Achievements: Teaching

• MBA Institute, Paris (France).

• San Jose State University, Business School (USA).

Intellectual Property

Patent granted

EP 4 321 186 B1 (EPO)

Patents pending

EP 4 313 205 A2 (EPO)

US 2024/0009438 A1 (USPTO)

US 2024/0082474 A1 (USPTO)

International application

WO2022207505

Sorin Grunwald PhD MBA

Founder and President

Email: grunwald.sorin@dialyfix.com

Contact

Copyright Dialyfix® 2024